Cancer gene therapy using mesenchymal stem cells expressing interferon-β in a mouse prostate cancer lung metastasis model

Ren, Changchun; Kumar, Sanjay; Chanda, Diptiman; Kallman, Lisa; Chen, Jian; Mountz, John D.; Ponnazhagan, Selvarangan

doi:10.1038/gt.2008.101

Cited by 195 publications

(126 citation statements)

References 40 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…Therapeutic proteins which raised great interest because of the possibility to be managed by MSCs are interferon (IFN ) [31,32] and (IFN ) [23,[31][32][33][34], interleukin (IL) 12 [35], cytokine IL2 [36] and chemokine CX3CL1 (fractalkine) [37]. There are a number of studies of effects of IFN and IFN incorporated into systems delivered by MSCs over tumor growth showing the inhibitory effect of IFN and its usefulness as adjuvant therapy for the elimination of micrometastasis in risk patients [38], while anticancer effect of IFN is determined as apoptosis-stimulation effect [39,40] and only toxicity observed after its systemic administration limits its clinical applications [41].…”

Section: Mscs Engineered As Anticancer Drug De-livery Systemsmentioning

confidence: 99%

Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems

Ackova¹,

Kanjevac²,

Rimondini³

et al. 2016

PRA

View full text Add to dashboard Cite

Understanding and apprehension of the characteristics and circumstances in which mesenchymal stem cells (MSCs) affect and make alterations (enhance or reduce) to the growth of tumors and metastasis spread is pivotal, not only for reaching the possibility to employ MSCs as drug delivery systems, but also for making forward movement in the existing knowledge of involvement of major factors (tumor microenvironment, soluble signaling molecules, etc.) in the process of carcinogenesis. This capability is reliable because MSCs present a great basis for engineering and constructions of new systems to target cancers, intended to secrete therapeutic proteins in the tumor region, or for delivering of oncolytic viruses' directly at the tumor site (targeted chemotherapy with enzyme prodrug conversion or induction of tumor cell apoptosis). MSCs as a crucial segment of the tumor surroundings and their confirmed tumor tropism, are assumed to be an open gateway for the design of promising drug delivery systems. The presented paper reviews current publications in this fieldwork, searches out the most recent patents that were published after 2012 (WO2014066122, US20140017787, WO2015100268, US20150086515), and tries to present the current progress and future prospective on the design and development in anti-cancer drug delivery systems based on MSCs.

show abstract

Section: Mscs Engineered As Anticancer Drug De-livery Systemsmentioning

confidence: 99%

Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems

Ackova¹,

Kanjevac²,

Rimondini³

et al. 2016

PRA

View full text Add to dashboard Cite

show abstract

“…In C26 colon and B16F10 melanoma mouse models, chemokine (C-X3-C-motif) ligand 1-expressing-MSCs reduced metastatic nodules and resulted in longer survival [51]. MSCs engineered to secrete interferon-β suppressed growth of breast, prostate, pancreatic and melanoma cancers in animal models [52][53][54][55], as did interleukin-12-expressing MSCs in renal cell cancer [56]. MSCs have also been transduced with interferon-γ [54], Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) [53,[57][58][59][60] and soluble decoy receptors such as type-I insulin-like growth factor receptor [61].…”

Section: The Promise Of Mscs In Cancer Therapymentioning

confidence: 99%

Mesenchymal Stem Cells: How Can we Realize their Therapeutic Potential in Cancer Therapy?

Baird

2015

J Clin Exp Pathol

View full text Add to dashboard Cite

Mesenchymal stem cells home to the tumour stroma from the bone marrow, influencing early tumour development and metastasis. Mesenchymal stem cells have been shown to be promising vehicles for cancer therapy due to this tropism for tumour sites, their immunoprivileged status, easy extraction from bone marrow and facile transfection. Mesenchymal stem cells have been used to deliver gene therapy in the form of cytokines or adenovirus and as part of prodrug strategies. However, in order for these agents to be tested in clinical trials, the biology of mesenchymal stem cells must be further investigated. At present there is variation between research groups surrounding mesenchymal stem cell isolation and characterisation methods, as well as in how the cells are delivered to in vivo models, making studies hard to compare. Research examining the attraction of mesenchymal stem cells to tumours has found that the cells home towards a wide range of growth factors, cytokines and proteases. Once part of the tumour stroma, mesenchymal stem cells may have both pro-and anti-tumorigenic effects, increasing tumour growth, angiogenesis and metastasis and decreasing immune activation in some systems, and in others, reducing tumour cell proliferation and development of metastases. Understanding more precisely which subsets of mesenchymal stem cells support or undermine the development of the tumour at various timepoints will enable an effective clinical trial strategy for mesenchymal stem cell-based cancer therapies to be developed and replicated with different cancers and treatment sites.

show abstract

“…To be able to minimize toxicity and increase the local concentration of IFN-, M S C s w e r e s e l e c t e d a s d e l i v e r y v e h i c l e . M u r i n e M S C s w e r e engineered to release IFN-and injected via tail vein into immunocompetent mice with prostate cancer lung metastasis (Ren et al, 2008b). Following IFN--expressing MSC therapy, the mice showed a reduction of tumor volume in the lung, increased tumor cell apoptosis, decreased tumor cell proliferation and blood vessel counts, and an increase in the natural killer cell activity.…”

Section: Genes Delivered By Mscs Treated Tumor Referencementioning

confidence: 99%

Mesenchymal Stem Cells as Vehicles for Targeted Therapies

Todd¹,

LeRoux²,

Danilkovitch‐Miagkova³

2011

Drug Discovery and Development - Present and Future

View full text Add to dashboard Cite

Cancer gene therapy using mesenchymal stem cells expressing interferon-β in a mouse prostate cancer lung metastasis model

Cited by 195 publications

References 40 publications

Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems

Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems

Mesenchymal Stem Cells: How Can we Realize their Therapeutic Potential in Cancer Therapy?

Mesenchymal Stem Cells as Vehicles for Targeted Therapies

Contact Info

Product

Resources

About